Table 3.

Estimates for hazard ratios for progression-free survival and overall survival in the nivolumab group.

Factors	PFS		OS
	Multivariate analysis		Multivariate analysis
	HR (95% CI)	P value	HR (95% CI)	P value
Age (≥60 vs <60)	0.52 (0.31~0.88)	0.014
LDH (≥160 vs <160)	2.88 (1.25~6.63)	0.013
ANC (≥3 vs <3)	0.20 (0.07~0.60)	0.004
dNLR (≥1.2 vs <1.2)			0.46 (0.22~0.99)	0.049

HR, hazard ratios; CI, confidence interval; PFS, progression-free survival; OS, overall survival; LDH, lactate dehydrogenase; ANC, absolute neutrophil count; dNLR, derived neutrophil-to-lymphocyte ratio.